Aerpio Pharmaceuticals (OTCMKTS:ARPO) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Aerpio Pharmaceuticals (OTCMKTS:ARPO) issued its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.01, Fidelity Earnings reports.

Shares of Aerpio Pharmaceuticals stock remained flat at $$0.54 during trading on Friday. The stock had a trading volume of 48,700 shares, compared to its average volume of 255,318. Aerpio Pharmaceuticals has a 12 month low of $0.45 and a 12 month high of $4.25. The company has a fifty day simple moving average of $0.58 and a 200-day simple moving average of $0.80.

Several analysts recently weighed in on the company. HC Wainwright set a $1.00 price target on Aerpio Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, October 21st. Zacks Investment Research raised Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, October 9th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $3.25.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Recommended Story: How the Consumer Price Index (CPI) is calculated?

Earnings History for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.